<DOC>
	<DOCNO>NCT02414997</DOCNO>
	<brief_summary>The purpose study determine effect remote ischemic preconditioning ( RIPC ) blood pressure vascular protection effect among Chinese young healthy adult primary hypertensive patient stage I .</brief_summary>
	<brief_title>The Effect Remote Ischemic Preconditioning ( RIPC ) Blood Pressure Its Vascular Protection Effect</brief_title>
	<detailed_description>Hypertension one common world-wide chronic disease , one major independent risk factor atherosclerotic cardiovascular disease ( ASCVD ) especially among middle-aged elderly . Recently , study indicate normotensive elderly without cardiovascular disease history , continuous RIPC 30 day lower systolic blood pressure 6 mmHg diastolic blood pressure 3 mmHg . Another study show 7-day RIPC intervention improve endothelium-dependent flow mediate dilation ( FDM ) cutaneous vascular conductivity ( CVC ) 13 healthy young male . In addition , study demonstrate microRNA-126 microRNA-34a endothelial specific microRNAs express human PBMCs . MicroRNA-126 responsible keep integrity vascular endothelial , promote proliferation , mobilization , migration endothelial progenitor cell ( EPCs ) , reduce arterial intimal hyperplasia , reduce adhesion neutrophil vascular endothelial . In contrast , microRNA-34a related age endothelial cell , find over-expressed senile endothelial cell . Together investigator use microRNA-126 microRNA-34a explore whether RIPC produce vascular endothelial protection effect . In summary , investigator propose hypothesis RIPC might blood pressure low effect protect vascular function Chinese healthy young adult primary hypertensive patient . The term `` primary hypertension stage I '' indicate blood pressure range 140 159 mmHg systolic and/or 90 99 mmHg diastolic . Accumulating evidence suggest subject primary hypertension stage I associate high incidence ASCVD . However , available data investigate nonpharmacologic therapy primary hypertension stage I , prospective , randomize , control , single-blind clinic trial investigate effect RIPC blood pressure vascular protection effect . The investigator hypothesize RIPC may lower SBP DBP , improve vascular function Chinese healthy young adult subject primary hypertension stage I . To address assumption , present study design study effect RIPC blood pressure vascular protection effect , use FMD , PWV , central arterial pressure , RHI ( EndoPAT ) quantification microRNA-126 microRNA-34a peripheral blood monocyte ( PBMC ) indicator among Chinese healthy young adult primary hypertensive patient stage I 1-month follow-up period .</detailed_description>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Subjects range 18 80 year old . Blood pressure normal primary hypertension stage I ( systolic blood pressure 140 159 mmHg and/or diastolic blood pressure 90 99 mmHg ) . No history smoking ( smoke eliminate effect RIPC ) quit smoke least 1 year . No intake caffeine caffeinecontaining substance process trial ( caffeine eliminate effect RIPC ) . Provide inform consent willingness cooperate study protocol . Less 18 year old 80 year old . Secondary hypertension . Pregnant lactating female . Systemic diseases diabetes , HIV/AIDS , liver disease , chronic renal failure , tuberculosis , autoimmune disease . Medical history cardiovascular disease : acute myocardial infarct , stable angina , unstable angina , heart failure , atrial fibrillation , atrioventricular blockade , peripheral vascular disease cerebrovascular accident . Patients unfavorable longterm followup poor compliance . Patients consider unfavorable take part trial investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>RIPC ( remote ischemic preconditioning )</keyword>
	<keyword>primary hypertension stage I</keyword>
	<keyword>vascular function</keyword>
	<keyword>microRNA-126</keyword>
	<keyword>microRNA-34a</keyword>
</DOC>